| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/17/2002 | WO2002004404A2 7,8 and 9-substituted tetracycline compounds |
| 01/17/2002 | WO2002004025A1 Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| 01/17/2002 | WO2002004024A1 Composition for the treatment of diabetes |
| 01/17/2002 | WO2002004005A2 Short peptides comprising histidine or alanine and their therapeutic use |
| 01/17/2002 | WO2002003991A2 Use of substituted indole compounds for increasing nitric oxide synthase activity |
| 01/17/2002 | WO2002003988A2 Use of substituted indole compounds for treating neuropeptide y-related conditions |
| 01/17/2002 | WO2002003984A2 Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x |
| 01/17/2002 | WO2002003978A2 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES |
| 01/17/2002 | WO2002003977A2 Combinations of statins, estrogenic agents and optionally estrogens |
| 01/17/2002 | WO2002003975A2 Combinations of ssri and estrogenic agents |
| 01/17/2002 | WO2002003972A2 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds |
| 01/17/2002 | WO2002003964A1 Oral pharmaceutical composition with controlled release and prolonged absorption |
| 01/17/2002 | WO2002003960A1 Particulate vectors for improving oral absorption of active principles |
| 01/17/2002 | WO2001054681A8 Composition for treatment of stress |
| 01/17/2002 | WO2001049838A3 Cis-acting regulatory nucleic acid sequences in the parathyroid hormone 3'-untranslated region |
| 01/17/2002 | WO2001047922A3 Azaindoles |
| 01/17/2002 | WO2001044448A3 Human oxidoreductase proteins |
| 01/17/2002 | WO2001038303A3 Vitamin d analogues |
| 01/17/2002 | WO2001034833A3 Regulating endogenous inhibitor at atp synthase |
| 01/17/2002 | WO2001032830A3 Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher basidiomycetes mushroom |
| 01/17/2002 | WO2001031051A3 Antisense modulation of protein kinase c-theta expression |
| 01/17/2002 | WO2001030362A3 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 01/17/2002 | WO2001027144A3 Ab5 toxin b subunit mutants with altered chemical conjugation characteristics |
| 01/17/2002 | WO2001021589A3 Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof |
| 01/17/2002 | WO2001021259A3 Use and compositions for treating platelet-related disorders using anagrelide |
| 01/17/2002 | WO2001012598A3 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 01/17/2002 | WO2001012171A3 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases |
| 01/17/2002 | WO2001007471A3 Cell cycle and proliferation proteins |
| 01/17/2002 | WO2001001973A3 Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 01/17/2002 | WO2000078971A3 Atp binding cassette transporter protein abc1 popypeptides |
| 01/17/2002 | WO2000078953A3 Human transport proteins |
| 01/17/2002 | WO2000078952A3 Human rna metabolism proteins (rmep) |
| 01/17/2002 | WO2000061129A3 S-hydroxynefazodone |
| 01/17/2002 | US20020006965 Methods and compositions for treating depression and other disorders using optically pure (-)-bupropion |
| 01/17/2002 | US20020006959 Therapy for reduced nervous cell metabolism |
| 01/17/2002 | US20020006957 Method for the synthesis of compounds of formula I and their uses thereof |
| 01/17/2002 | US20020006953 Modification of cholesterol concentrations with citus phytochemicals |
| 01/17/2002 | US20020006951 Solid-state form of celecoxib having enhanced bioavailability |
| 01/17/2002 | US20020006946 Obesity, antidiabetic agents, cardiovascular disorders |
| 01/17/2002 | US20020006917 Method of locking 1alpha-OH of vitamin D compounds in axial orientation |
| 01/17/2002 | US20020006899 Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| 01/17/2002 | US20020006640 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 01/17/2002 | US20020006441 Pharmaceutical composition containing diphosphonic acid or salt thereof |
| 01/17/2002 | DE10033337A1 Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel Biphenylcarbonsäureamide, their preparation and their use as medicaments |
| 01/17/2002 | DE10005302A1 Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives |
| 01/17/2002 | CA2416199A1 Adenosine compound and pharmaceutical composition containing the same |
| 01/17/2002 | CA2415425A1 Insulin derivatives and synthesis thereof |
| 01/17/2002 | CA2415093A1 Anticonvulsant derivatives useful for preventing the development of type ii diabetes mellitus and syndrome x |
| 01/17/2002 | CA2415086A1 7,8 and 9-substituted tetracycline compounds |
| 01/17/2002 | CA2414938A1 Combinations of ssri and estrogenic agents |
| 01/17/2002 | CA2414387A1 Drug metabolizing enzymes |
| 01/17/2002 | CA2414198A1 Melanin concentrating hormone receptor ligands |
| 01/17/2002 | CA2414111A1 Use of substituted indole compounds for increasing nitric oxide synthase activity |
| 01/17/2002 | CA2414060A1 Combinations of statins, estrogenic agents and optionally estrogens |
| 01/17/2002 | CA2413044A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives |
| 01/17/2002 | CA2412142A1 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| 01/17/2002 | CA2411160A1 Colchinol derivatives as vascular damaging agents |
| 01/17/2002 | CA2380859A1 Anti-obesity material |
| 01/16/2002 | EP1172373A2 Method for preparing zinc-oligopeptide easily absorbable by the human body |
| 01/16/2002 | EP1172114A2 Stable concentrated insulin preparations for pulmonary delivery |
| 01/16/2002 | EP1172113A1 Remedies for autonomic neuropathy |
| 01/16/2002 | EP1172110A2 Use of lipoic acid as a bioavailaty enhancer of mineral salts |
| 01/16/2002 | EP1172106A2 Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists |
| 01/16/2002 | EP1172041A2 Compositions of plant carbohydrates as dietary supplements |
| 01/16/2002 | EP1171626A1 50 human secreted proteins |
| 01/16/2002 | EP1171614A1 Dsp-4 dual-specificity map kinase phosphatase |
| 01/16/2002 | EP1171613A1 Dsp-7 dual-specificity map kinase phosphatase |
| 01/16/2002 | EP1171596A1 Synthetic transmembrane components |
| 01/16/2002 | EP1171590A1 50 human secreted proteins |
| 01/16/2002 | EP1171583A2 A multi-plasmid method for preparing large libraries of polyketides and non-ribosomal peptides |
| 01/16/2002 | EP1171573A1 Arpe-19 as a platform cell line for encapsulated cell-based delivery |
| 01/16/2002 | EP1171458A1 50 human secreted proteins |
| 01/16/2002 | EP1171457A1 46 human secreted proteins |
| 01/16/2002 | EP1171455A1 Polypeptide-k obtained from momordica charantia and a process for the extraction thereof |
| 01/16/2002 | EP1171444A1 Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines |
| 01/16/2002 | EP1171438A1 Compounds, their preparation and use |
| 01/16/2002 | EP1171435A2 Pyrimidine-2-one derivatives as integrin receptor ligands |
| 01/16/2002 | EP1171431A1 Compounds, their preparation and use |
| 01/16/2002 | EP1171430A1 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them |
| 01/16/2002 | EP1171425A1 Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins |
| 01/16/2002 | EP1171424A1 Cyclo-alkyl substituted benzimidazoles and their use as parp inhibitors |
| 01/16/2002 | EP1171416A1 3-bicycloaryl-2-aminomethyl bicycloalkanes as serotonine reuptake inhibitors |
| 01/16/2002 | EP1171414A1 Compounds, their preparation and use |
| 01/16/2002 | EP1171156A1 Novel use within transplantation surgery |
| 01/16/2002 | EP1171136A2 Immunomodulating composition for use especially in the treatment of inflammations, infections and surgical adhesions |
| 01/16/2002 | EP1171131A1 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk |
| 01/16/2002 | EP1171130A1 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| 01/16/2002 | EP1171129A1 Use of glucosylceramide synthesis inhibitors in therapy |
| 01/16/2002 | EP1171128A1 Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy |
| 01/16/2002 | EP1171127A2 Pharmaceutical compositions containing pyridine or pyrimidine derivatives for inhibition of cytokine production and secretion |
| 01/16/2002 | EP1171119A1 Methods of treating clinical diseases with isoflavones |
| 01/16/2002 | EP1171115A1 Methods of delivery of cetyl myristoleate |
| 01/16/2002 | EP1171113A1 Compounds useful as phosphotyrosine mimics |
| 01/16/2002 | EP1171100A1 Solubilized pharmaceutical composition for parenteral administration |
| 01/16/2002 | EP1171078A2 Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol |
| 01/16/2002 | EP1171003A1 Complete feed for fish larvae and method for preparing same |
| 01/16/2002 | EP1170993A1 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding 4e-bp1 |
| 01/16/2002 | EP0638075B1 Thiazole or imidazole derivatives as maillard reaction inhibitors |
| 01/16/2002 | CN1331801A Kidney disease detection and treatment |
| 01/16/2002 | CN1331703A Substance for reduction of cholesterol as well as lipids content |